It is a pleasure to announce that HCS Pharma has a new collaborative project dealing with Inflammasome et ion channels Team of OncoLille (PHYCELL Lab, INSERM U1003) in the frame of colon cancer, thanks to France Relance plan and Region Hauts-de-France. This project has started in October 2022 for 2 years, and is supervised by Dr. Mathias Chamaillard (Oncolille) and Véronique De Conto (HCS Pharma). We are happy to welcome Sofian Allam, who has been employed as an engineer for this project. Welcome Sofian!
The objective of this project is to develop a 3D complex model of dysbiosis-induced colon cancer, composed of cancerous cells, cancer-associated fibroblasts, macrophages, and bacteria. This model will be developed in 3D in BIOMIMESYS® matrix, a hyaluronic-acid based hydroscaffold™ grafted with structural components that mimics the extracellular matrix. The composition and the stiffness of BIOMIMESYS® are modular, that is why it can be adapted to reproduced the tumoral extracellular matrix, which is enriched in type I collagen I and more rigid. In the end, this complex and relevant in vitro model will be used to screen molecules in order to develop innovative drugs against colon cancer, targeting not only the cancer cells but also the tumoral microenvironment.
Feel free to contact us if you want more information about the 3D cell culture technology BIOMIMESYS®.
0 Comments